Abstract: Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
Type:
Application
Filed:
September 23, 2003
Publication date:
March 4, 2004
Applicant:
CELL THERAPEUTICS, INC.
Inventors:
David W. Leung, Daniel Adourel, David Hollenback
Abstract: Disclosed are therapeutic compounds having the formula:
(R)j—(CORE MOIETY),
including resolved enantiomers, diastereomers, hydrates, salts, solvates or mixtures thereof where j is an integer from one to three. The core moiety is a bicyclic ring structure having at least one heterocyclic ring that contains five to six ring atoms and up to two nitrogen heteroatoms. R is selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C1-6 alkyl or C1-6 alkenyl, and at least one R has the formula I:
n is an integer from 1 to 20, at least one of X or Y is —OH. Another of X or Y, which is not —OH, is hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2—or (CH3)2—CH2—, and each W1, W2, and W3 is independently hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2— or (CH3)2—CH2—.
Type:
Grant
Filed:
July 27, 1999
Date of Patent:
February 17, 2004
Assignee:
Cell Therapeutics, Inc.
Inventors:
Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson, Stephen J. Klaus, Anil M. Kumar, John Tulinsky
Abstract: The present invention relates to arsenic sulfide compounds. The present invention also relates to pharmaceutical compositions useful for treating cancer, such as leukemia or lymphoma, which comprises an arsenic sulfide compound. The present invention further relates to methods for treating cancer, such as leukemia or lymphoma, using an arsenic sulfide compound. Finally, the present invention relates to processes for producing arsenic disulfide (As4S4).
Abstract: The invention is directed to thiazolidinones and the use thereof to inhibit phospholipase D (PLD) activity. The invention further relates to methods of treating cancer and inflammatory diseases using thiazolidinones.
Type:
Application
Filed:
April 1, 2003
Publication date:
January 1, 2004
Applicant:
Cell Therapeutics, Inc.
Inventors:
J. Peter Klein, Anil M. Kumar, Marc J. McKennon
Abstract: Polypeptides are obtained, for example, via expression of encoding cDNA sequences, that have the activity of the enzyme lysophosphatidic acid acyltransferase (LPAAT), also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.
Type:
Grant
Filed:
October 5, 2001
Date of Patent:
December 30, 2003
Assignee:
Cell Therapeutics, Inc.
Inventors:
David W. Leung, Daniel Adourel, David Hollenback
Abstract: The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.
Type:
Application
Filed:
April 2, 2003
Publication date:
December 4, 2003
Applicant:
CELL THERAPEUTICS, INC.
Inventors:
Anil M. Kumar, J. Peter Klein, Rama Bhatt, Edward Vawter
Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).
Type:
Application
Filed:
May 9, 2003
Publication date:
November 20, 2003
Applicant:
Cell Therapeutics,Inc.
Inventors:
Stuart L. Bursten, Jack W. Singer, Glenn C. Rice
Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).
Type:
Grant
Filed:
December 12, 1994
Date of Patent:
October 28, 2003
Assignee:
Cell Therapeutics, Inc.
Inventors:
Stuart L. Bursten, Jack W. Singer, Glenn C. Rice
Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity and/or proliferation of cells such as tumor cells.
Type:
Application
Filed:
October 30, 2002
Publication date:
August 14, 2003
Applicant:
Cell Therapeutics, Inc.
Inventors:
Rama Bhatt, Baoqing Gong, Feng Hong, Scott A. Jenkins, J. Peter Klein, Anil M. Kumar, John Tulinsky
Abstract: Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling. The compounds have the following formulas
where R1, R2 and R3 are defined in the written description of the invention.
Type:
Grant
Filed:
November 29, 2000
Date of Patent:
July 1, 2003
Assignee:
Cell Therapeutics, Inc.
Inventors:
Baoqing Gong, J. Peter Klein, Michael Coon
Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-&bgr; activity.
Type:
Application
Filed:
September 6, 2002
Publication date:
May 29, 2003
Applicant:
Cell Therapeutics, Inc.
Inventors:
Robert Finney, David Leung, J. Peter Klein, David M. Hollenback, Lynn Bonham, Scott A. Shaffer, Norina M. Tang, Thayer H. White, John Tulinsky, Baoqing Gong
Abstract: The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Type:
Application
Filed:
September 30, 2002
Publication date:
May 29, 2003
Applicant:
Memorial Sloan-Kettering Cancer Center Cell Therapeutics, Inc.
Inventors:
Raymond P. Warrell, Pier P. Pandolfi, Janice L. Gabrilove, Ralph Ellison, Steven Soignet
Abstract: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.
Type:
Application
Filed:
May 17, 2002
Publication date:
April 17, 2003
Applicant:
Cell Therapeutics, Inc.
Inventors:
Chun Li, Sidney Wallace, Dong-Fang Yu, David J. Yang
Abstract: The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.
Type:
Application
Filed:
July 18, 2002
Publication date:
March 20, 2003
Applicant:
Cell Therapeutics, Inc.
Inventors:
Anil Kumar, J. Peter Klein, Rama Bhatt, Edward Vawter
Abstract: The present invention provides a method of increasing neural stem cell numbers by using growth hormone and/or IGF-1. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions.
Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.
Abstract: This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.
Type:
Application
Filed:
August 30, 2002
Publication date:
March 13, 2003
Applicant:
Stem Cell Therapeutics Inc.
Inventors:
Bradley G. Thompson, Samuel Weiss, Tetsuro Shingo